Indaptus Therapeutics, Inc. (INDP) — Analyst outlook / Analyst consensus target is. Based on 2 analyst ratings, the consensus is bullish — 2 Buy.
Analysts estimate Earnings Per Share (EPS) of $-47.88 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.61 vs est $-47.88 (beat +96.6%). 2025: actual $-21.58 vs est $-20.79 (missed -3.8%). Analyst accuracy: 0%.
INDP Analyst Ratings
Buy
Based on 2 analysts giving stock ratings to Indaptus Therapeutics, Inc. in the past 3 months
EPS Estimates — INDP
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.61
vs Est –$47.88
▲ 2,873.9% off
2025
Actual –$21.58
vs Est –$20.79
▼ 3.7% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — INDP
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
